Moleculin Biotech
MBRX
19 hedge funds and large institutions have $2.05M invested in Moleculin Biotech in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 18 → 19 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.2% less ownership
Funds ownership: 4.98% → 4.78% (-0.2%)
11% less capital invested
Capital invested by funds: $2.3M → $2.05M (-$243K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.54K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.54K |
| 4 |
AWM
Avondale Wealth Management
West Lake Hills,
Texas
|
+$3.77K |
| 5 |
BlackRock
New York
|
+$3.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$24K |
| 2 |
CF
Centaurus Financial
Anaheim,
California
|
-$13K |
| 3 |
CIBC World Market
Toronto,
Ontario, Canada
|
-$7.54K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$3.77K |
MBRX Hedge Fund Activity: Q3 2018 in Review
19 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2018, worth a combined $2.05M — down 11% from $2.3M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MBRX positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $18.8K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $24K sold.
- 19 institutional investors held Moleculin Biotech (MBRX) as of Q3 2018, up from 18 in Q2 2018.
- Funds reported $2.05M of Moleculin Biotech stock for Q3 2018, down 11% quarter-over-quarter.
- 3 funds opened new Moleculin Biotech positions in Q3 2018 and 2 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q3 2018 was Citadel Advisors, an estimated $18.8K added.
- The largest Moleculin Biotech seller in Q3 2018 was Two Sigma Securities, an estimated $24K sold.
Based on aggregated 13F filings for Q3 2018.